RecruitingNCT07105098
NBI-1117568 for adults hospitalized with schizophrenia
About this title
Read the official source — NCT07105098Researchers are comparing NBI-1117568 and placebo to find out how the approaches affect psychotic symptoms in adults with schizophrenia.
Medication studyAges 18–65Multiple countries
Understand this study
What is this study about?
Researchers are comparing NBI-1117568 and placebo to find out how the approaches affect psychotic symptoms in adults with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
In this five-week inpatient study, participants are randomly assigned to oral NBI-1117568 or matching placebo (an inactive comparison treatment) once a day for 35 days.
- Listed locations
- Little Rock and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 11, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 284
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Hungary, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07105098
- Official title
Show the full official title
A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Little Rock, United States · Culver City, United States · Garden Grove, United States
16 more locations
- Riverside, United States
- Hollywood, United States
- Atlanta, United States
- North Canton, United States
- Pleven, Bulgaria
- Sliven, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Budapest, Hungary
- Gyöngyös, Hungary
- Győr, Hungary
- Brasov, Romania
- Bucharest, Romania
- Belgrade, Serbia
- Gornja Toponica, Serbia
- Kragujevac, Serbia
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing NBI-1117568 and placebo to find out how the approaches affect psychotic symptoms in adults with schizophrenia.
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Does this study involve medication?
Yes. The study involves medication, including NBI-1117568 and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Long-term safety of LB-102 in adults with schizophrenia
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....